UK Research Peptide Compliance After Brexit: MHRA, Customs, and What Changed
Compliance & Regulation | 2026-07-09 | 9 min read
A 2026 guide to UK research peptide compliance after Brexit, covering MHRA research-use policy, post-Brexit customs procedure, GB EORI requirements, and the compliance posture UK institutional buyers should adopt.
Why the UK is now a separate regulatory jurisdiction
Brexit moved the UK out of the EU regulatory framework. Research peptide supply to the UK now follows UK-specific rules that overlap but do not match the EU framework. A buyer who treats the UK as "still EU" loses time at customs and risks non-compliance.
MHRA research-use policy
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK's medicines regulator. Research peptides sold for laboratory use only are not medicinal products, but the MHRA enforces labeling rules:
- "For research use only" statement on the label
- No drug, supplement, or food representation
- Supplier name and contact
- Lot number and storage condition
- UK responsible person if applicable
The MHRA focuses enforcement on retail sale, not laboratory supply. Institutional buyers operating in licensed research facilities rarely face MHRA action, but the labeling still has to be correct.
Post-Brexit customs procedure
UK customs for research peptides:
- Commercial invoice with HS code and declared value
- Packing list with lot numbers and net weight
- Certificate of analysis (COA)
- Material safety data sheet (MSDS)
- Research-use declaration
- GB EORI number from the buyer
GB EORI is required for any UK import. Without it, the shipment cannot clear customs.
VAT and duty
UK VAT is charged on most imports at 20%. Duty depends on the HS code and country of origin. For research peptides manufactured outside the UK, duty is typically 0-6.5% depending on the HS classification.
A peptide supplier with UK experience should know the HS code that minimizes duty and provide the buyer with the appropriate invoice structure.
The Northern Ireland Protocol
Northern Ireland remains aligned with the EU regulatory framework for goods. A peptide shipment to Northern Ireland follows EU customs rules, not UK rules. This is a frequent source of confusion for institutional buyers.
ZePeptide routes Northern Ireland shipments through the EU compliance pack to avoid mismatched paperwork.
Country-specific documentation expectations
UK customs is generally efficient, but a few documentation patterns matter:
- Research-use declaration on company letterhead
- COA signed by a UK-recognized analyst (some suppliers have UK-based analytical partners)
- Storage and handling instructions aligned with UK laboratory norms
- Cold-chain packaging validation report
Without these, customs may hold the shipment for additional documentation review.
Common compliance mistakes
- Treating the UK as still EU for customs purposes
- Missing GB EORI, causing customs delay
- Accepting EU-only labeling on shipments
- Assuming MHRA regulates research peptides the same way as medicinal products
- Forgetting Northern Ireland protocol
How ZePeptide supports UK compliance
ZePeptide UK compliance pack includes:
- Post-Brexit customs paperwork
- GB EORI support documentation
- Research-use-only labeling consistent with UK norms
- Northern Ireland protocol routing
- Cold-chain packaging validation report
Talk to the regulatory team for high-value or scheduled-compound shipments.
ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.